Superantigens of Gram-positive bacteria: Structure-function analyses and their implications for biological activity

Current Opinion in Microbiology

Volumn 1, Issue 1, 1998, Pages 56-65

  Kotb, Malak ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSIBACTERIA;

BACTERIAL ANTIGEN; HLA ANTIGEN CLASS 2; SUPERANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BACTERIAL INFECTION; CHEMISTRY; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOPHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP; SUPERANTIGENS;

EID: 0031987803     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80143-4     Document Type: Article

References (79)

1. Kotzin BL, Leung DY, Kappler J, Marrack P: Superantigens and their potential role in human disease. Adv Immunol 1993, 54:99-166.
2. Kotb M: Role of superantigens in the pathogenesis of infectious diseases and their sequelae. Curr Opin Infect Dis 1992, 5:364-74.
3. Schlievert PM: Role of superantigens in human diseases. J Infect Dis 1993, 167:997-1002.
4. Marrack P, Kappler J: The staphylococcal enterotoxins and their relatives. Science 1990, 248:705-711.
5. Janeway CA, Yagi J, Conrad PJ, Katz MF, Jones B, Vroegop S, Buxser S: T cell responses to M/s and to bacterial proteins that mimic its behavior. Immunol Rev 1989, 107:61-88.
6. Kotb M: Bacterial exotoxins as superantigens. Clin Microbiol Rev 1995, 8:411-426.
7. Bohach GA, Fast DJ, Nelson RD, Schlievert PM: Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990, 17:251-272.
8. Herman A, Kappler JW, Marrack P, Pullen AM: Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu Rev Immunol 1991, 9:745-772.
9. Johnson HM, Torres BA, Soos JM: Superantigens: structure and relevance to human disease. Proc Soc Exp Biol Med 1996, 212:99-109.
10. Iandolo J, Chapes S: The exfoliative toxins of Staphylococcus aureus. In Superantigens. Edited by Leung DYM, Huber BT, Schlievert PM. Marcel Dekka, Inc: New York; 1997:231-255.
11. Vath GM, Earhart CA, Rago JV, Kim MH, Bohach GA, Schlievert PM, Ohlendorf DH: The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry 1997, 36:1559-1566.
12. Watanabe-Ohnishi R, Aelion J, LeGros HL, Tomai MA, Sukerienko E, Newton D, Takahara J, Irino S, Rashed S, Kotb M: Characterization of unique human TCR-Vβ specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein. J Immunol 1994, 152:2066-2072.
13. Tomai M, Schlievert PM, Kotb M: Distinct T cell receptor Vβ gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and M protein. Infect Immun 1992, 60:701-705.
14. Abe J, Forrester J, Takako N, Lafferty JA, Kotzin BL, Leung DYM: Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol 1991, 146:3747-3750.
15. Norrby A, Newton D, Kotb M, Holms S, Norgren M: Superantigenic properties of the group A streptococcal exotoxin, MF (SPeF). Infect Immun 1994, 62:5227-5233.
16. Reda KB, Kapur V, Mollick JA, Lamphear JG, Musser JM, Rich RR: Molecular characterization and phylogenetic distribution of the streptococcal superantigen gene (ssa) from Streptococcus pyogenes. Infect Immun 1994, 62:1867-1874.
17. Newton D, Norrby-Teglund A, McGeer A, Low DE, Schlievert PM, Kotb M: Novel superantigens from streptococcal toxic shock syndrome Streptococcus pyogenes isolates. Adv Exp Med Biol 1997, 418:525-529.
18. Betley MJ, Borst DW, Regassa LB: Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal pyrogenic exotoxins: a comparative study of their molecular biology. Chem Immunol 1992, 55:1-35.
19. Schlievert PM, Bohach GA, Ohlendorf DH, Stauffacher CV, Leung DY, Murray DL, Prasad GS, Earhart CA, Jablonski LM, Hoffmann ML, Chi YI: Molecular structure of staphylococcus and streptococcus superantigens. J Clin Immunol 1995, 15:S4-S10.
20. Schad EM, Zaitseva I, Zaitsev VN, Dohlsten M, Kalland T, Schlievert PM, Ohlendorf DH, Svensson LA: Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J 1995, 14:3292-3301.
21. 2+ coordinates SEA-MHC interactions.
22. Swaminathan S, Furey W, Pletcher J, Sax M: Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature 1992, 359:801-806.
23. Papageorgiou AC, Acharya KR, Shapiro R, Passalacqua EF, Brehm RD, Tranter HS: Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site. Structure 1995, 3:769-779.
24. 2+ sites were identified and the role of this metal in the biological activity of superantigens is highlighted. Also, the paper demonstrates a new mode by which superantigens can bind and cross-link major histocompatibility complex (MHC).
25. Prasad GS, Earhart CA, Murray DL, Novick RP, Schlievert PM, Ohlendorf DH: Structure of toxic shock syndrome toxin 1. Biochemistry 1993, 32:13761-13766.
26. Acharya KR, Passalacqua EF, Jones EY, Harlos K, Stuart DI, Brehm RD, Tranter HS: Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 1994, 367:94-97.
27. Papageorgiou AC, Brehm RD, Leonidas DD, Tranter HS, Acharya KR: The refined crystal structure of toxic shock syndrome toxin-1 at 2.07 Ȧ resolution. J Mol Biol 1996, 260:553-569.
28. 2+, which mediates the binding of the superantigen to the β chain of the molecule. This study demonstrates a novel mechanism by which superantigen can promote MHC aggregation and T cell activation.
29. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC: Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368:711-718.
30. Kim J, Urban RG, Strominger JL, Wiley DC: Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 1994, 266:1870-1874.
31. Fields BA, Malchiodi EL, Li H, Ysern X, Stauffacher CV, Schlievert PM, Karjalainen K, Mariuzza RA: Crystal structure of a T-cell receptor β-chain complexed with a superantigen. Nature 1996, 384:188-192. This study provides structural evidence for the mode of superantigen Vβ interaction. The β chain of the T-cell receptor (TCR) (Vβ8.2) was cocrystallized with staphylococcal enterotoxin (SE) C3 and the a model of TCR-superantigen-major histocompatibility complex (MHC) interaction is constructed to reveal that superantigen acts as a wedge between the TCR and MHC.
32. Schad EM, Papageorgiou AC, Svensson LA, Acharya KR: A structural and functional comparison of staphylococcal enterotoxins A and C2 reveals remarkable similarity and dissimilarity. J Mol Biol 1997, 269:270-280. The authors provide a thorough discussion of the mode of interaction of superantigens with major histocompatibility complex (MHC) and T-cell receptor. Similarities and differences between staphylococcal enterotoxin (SE) A and SEC2 are highlighted, and the SEC mode of interaction with MHC is discussed.
33. Papageorgiou AC, Acharya KR: Superantigens as immunomodulators: recent structural insights. Structure 1997, 5:991-996.
34. Hovde CJ, Marr JC, Hoffmann ML, Hackett SP, Chi YI, Crum KK, Stevens DL, Stauffacher CV, Bohach GA: Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Mol Microbiol 1994, 13:897-909.
35. Harris TO, Betley MJ: Biological activities of staphylococcal enterotoxin type A mutants with N-terminal substitutions. Infect Immun 1995, 63:2133-2140.
36. Hoffman M, Tremaine M, Mansfield J, Betley M: Biochemical and mutational analysis of the histidine residues of staphylococcal enterotoxin A. Infect Immun 1996, 64:885-890.
37. Kappler JW, Herman A, Clements J, Marrack P: Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J Exp Med 1992, 175:387-396.
38. Abrahmsen L, Dohlsten M, Segren S, Bjork P, Jonsson E, Kalland T: Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J 1995, 14:2978-86.
39. ••], these studies point to the fact that superantigens have developed distinct modes of interaction with MHC.
40. ••].
41. Svensson LA, Schad EM, Sundstrom M, Antonsson P, Kalland T, Dohlsten M: Staphylococcal enterotoxins A, D, and E. Structure and function, including mechanism of T-cell superantigenicity. Prep Biochem Biotechnol 1997, 27:111-141.
42. Abrahmsen L: Superantigen engineering. Curr Opin Struct Biol 1995, 5:464-470.
43. Newton DW, Dohlsten M, Olsson C, Segren S, Lundin KE, Lando PA, Kalland T, Kotb M: Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vβ specificity. J Immunol 1996, 157:3988-3994. This study demonstrates the effect of staphylococcal enterotoxin (SE) A binding to the α and β chains of major histocompatibility complex (MHC) on recognition of the superantigen by specific Vβ elements. Mutations in SEA that affect its ability to interact with the low affinity class II α chain binding site resulted in stimulation of only two of the six Vβs that normally recognize the superantigen. By contrast, mutations that affect binding to the β chain of class II did not alter the Vβ recognition pattern. Together the data suggest that, for some superantigens, binding to the MHC α chain may be important to attain a specific orientation or conformation for recognition by certain Vβ subsets.
44. ab fragments: implications for use in treatment of human colon carcinoma. Int J Mol Med 1998, 1:157-162. This study demonstrates that recognition by certain Vβ elements is independent of the superantigen-major histocompatibility complex (MHC) interaction; whereas other Vβ elements will only recognize superantigen when it is bound in a specific orientation to the MHC.
45. Prasad GS, Radhakrishnan R, Mitchell DT, Earhart CA, Dinges MM, Cook WJ, Schlievert PM, Ohlendorf DH: Refined structures of three crystal forms of toxic shock syndrome toxin- 1 and of a tetramutant with reduced activity. Protein Sci 1997, 6:1220-1227.
46. Malchiodi EL, Eisenstein E, Fields BA, Ohlendorf DH, Schlievert PM, Karjalainen K, Mariuzza RA: Superantigen binding to a T cell receptor β chain of known three-dimensional structure. J Exp Med 1995, 182:1833-1845.
47. Antonsson P, Wingren AG, Hansson J, Kalland T, Varga M, Dohlsten M: Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR. J Immunol 1997, 158:4245-4251. This study illustrates striking differences between staphylococcal enterotoxin (SE) A and SEE in their ability to mediate major histocompatibility complex (MHC)-independent T cells activation. Together with Malchiodi et al. 1995 [46], the study points to the fact that superantigens, including ones that are highly homologous to each other, have distinct modes of interaction with MHC and T-cell receptor.
48. Fremont DH, Rees WA, Kozono H: Biophysical studies of T-cell receptors and their ligands. Curr Opin Immunol 1996, 8:93-100.
49. Kotb M, Majumdar G, Tomai M, Beachey EH: Accessory cell-independent stimulation of human T cells by streptococcal M protein superantigen. J Immunol 1990, 145:1332-1336.
50. Majumdar G, Beachey EH, Tomai MA, Kotb M: Differential signal requirements in T-cell activation by mitogen and superantigen. Cell Signalling 1991, 2:521-530.
51. Ohnishi H, Tanaka T, Takahara J, Kotb M: CD28 delivers costimulatory signals for superantigen-induced activation of antigen-presenting cell-depleted human T lymphocytes. J Immunol 1993, 150:3207-3214.
52. Ohnishi H, Ledbetter JA, Kanner SB, Linsley PS, Tanaka T, Geller AM, Kotb M: CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses. J Immunol 1995, 154:3180-3193.
53. Kotb M, Watanabe-Ohnishi R, Aelion J, Tanaka T, Geller AM, Ohnishi H: Preservation of the specificity of superantigen to T cell receptor V beta elements in the absence of MHC class II molecules. Cell Immunol 1993, 152:348-357.
54. Lando PA, Olsson C, Kalland T, Newton D, Kotb M, Dohlsten M: Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. J Immunol 1996, 157:2857-2863.
55. Mehindate K, Thibodeau J, Dohlsten M, Kalland T, Sekaly RP, Mourad W: Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med 1995, 182:1573-1577.
56. Hudson KR, Tiedemann RE, Urban RG, Lowe SC, Strominger JL, Fraser JD: Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J Exp Med 1995, 182:711-720.
57. Bohach G: Staphylococcal entertoxin B and C. In Superantigens. Edited by Leung DYM, Huber BT, Schlievert PM. 1997:167-198.
58. Herman A, Croteau G, Sekaly RP, Kappler J, Marrack P: HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J Exp Med 1990, 172:709-717.
59. Herman A, Labrecque N, Thibodeau J, Marrack P, Kappler JW, Sekaly RP: Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR. Proc Natl Acad Sci USA 1991, 88:9954-9958.
60. Scholl P, Diez A, Karr R, Sekaly RP, Trowsdale J, Geha RS: Effect of isotypes and allelic polymorphism on the binding of staphylococcal enterotoxins to MHC class II molecules. J Immunol 1990, 144:226-230.
61. Labrecque N, Thibodeau J, Sekaly RP: Interactions between staphylococcal superantigens and MHC class II molecules. Semin Immunol 1993, 5:23-32.
62. Cole BC, Sawitzke AD, Ahmed EA, Atkin CL, David CS: Allelic polymorphisms at the H-2A and HLA-DQ loci influence the response of murine lymphocytes to the Mycoplasme arthritidis superantigen MAM. Infect Immun 1997, 65:4190-4198. Together with data from Mehindate et al. 1995 [55], Herman et al. 1991 [59], Scholl et al. 1990 [60] and Imanishi et al. 1992 [64], this study indicates that isotypic and allelic differences in class II can have profound effects on superantigen presentation.
63. Taub DD, Newcomb JR, Rogers TJ: Effect of isotypic and allotypic variations of MHC class II molecules on staphylococcal enterotoxin presentation to murine T cells. Cell Immunol 1992, 141:263-278.
64. Imanishi K, Igarashi H, Uchiyama T: Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B. Infect Immun 1992, 60:5025-5029.
65. Kline JB, Collins CM: Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A. Infect Immun 1996, 64:861-869.
66. Guedez Y, Norrby-Teglund A, Low D, McGeer A, Kotb M: HLA class II alleles associated with outcome of invasive group A streptococcal infections. The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC97), 1997 Sept 29-Oct 1; Toronto, Ontario, Canada. American Society for Microbiology. This award winning presentation demonstrates that the major histocompatibility complex (MHC) class II haplotype of the host can confer risk or protection from severe manifestations elicited by streptococcal superantigen in invasive infection cases. The results underscore the importance of superantigen-MHC interaction in regulating the magnitude of cytokine responses and controlling the clinical outcome of infection by superantigen-producing organisms.
67. Thibodeau J, Cloutier I, Lavoie PM, Labrecque N, Mourad W, Jardetzky T, Sekaly RP: Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science 1994, 266:1874-1878.
68. Wen R, Blackman MA, Woodland DL: Variable influence of MHC polymorphism on the recognition of bacterial superantigens by T cells. J Immunol 1995, 155:1884-1892.
69. Wen R, Cole GA, Surman S, Blackman MA, Woodland DL: Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells. J Exp Med 1996, 183:1083-1092.
70. Wen R, Broussard DR, Surman S, Hogg TL, Blackman MA, Woodland DL: Carboxy-terminal residues of major histocompatibility complex class II- associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells. Eur J Immunol 1997, 27:772-781. Together with Wen et al. 1996 [69] and Broussard D, Surman S, Woodland DL (personal communication) this study indicates the role of major histocompatibility complex (MHC)-bound peptides in modulating superantigen presentation. In addition, the paper provides insight into the structural basis for the peptide effect.
71. ••] these studies indicate that cellular factors can modulate superantigen responses.
72. Yagi J, Uchiyama T, Janeway CA Jr: Stimulator cell type influences the response of T cells to staphylococcal enterotoxins. J Immunol 1994, 152:1154-1162.
73. Woodland DL, Wen R, Blackman MA: Why do superantigens care about peptides? Immunol Today 1997 18:18-21. This is a thought stimulating review of the role of cellular factors that can potentially modulate superantigen presentation. The authors suggest that factors that seem to attenuate the superantigen response may in fact be contributing to optimization of the response.
74. Kozono H, Parker D, White J, Marrack P, Kappler J: Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. Immunity 1995, 3:187-196.
75. von Bonin A, Ehrlich S, Malcherek G, Fleischer B: Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1. Eur J Immunol 1995, 25:2894-2898.
76. Chintagumpala MM, Mollick JA, Rich RR: Staphylococcal toxins bind to different sites on HLA-DR. J Immunol 1991, 147:3876-3881.
77. Thibodeau J, Labrecque N, Denis F, Huber BT, Sekaly RP: Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules. J Exp Med 1994, 179:1029-1034.
78. Hamad AR, Marrack P, Kappler JW: Transcytosis of staphylococcal superantigen toxins. J Exp Med 1997, 185:1447-1454. This study provides a plausible mechanism to explain differential effects of superantigens on different tissues.
79. Stollerman GH: Rheumatic fever. Lancet 1997, 349:935-942.